Research programme: glycosylated adiponectin - Protemix

Drug Profile

Research programme: glycosylated adiponectin - Protemix

Alternative Names: Glycosylated adiponectin; PX 811013

Latest Information Update: 27 Jun 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Protemix Corporation
  • Class
  • Mechanism of Action Fatty acid synthetase complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alcoholic hepatitis; Non-alcoholic steatohepatitis

Most Recent Events

  • 30 Jun 2010 Discontinued - Preclinical for Alcoholic hepatitis in New Zealand (unspecified route)
  • 30 Jun 2010 Discontinued - Preclinical for Non-alcoholic steatohepatitis in New Zealand (unspecified route)
  • 19 May 2006 Preclinical trials in Alcoholic hepatitis in New Zealand (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top